Meeting Banner
Abstract #4023

A metabolomic evaluation of prostate cancer field effects

Sarah S. Dinges1,2, Lindsey A. Vandergrift1, Shulin Wu1, Yannick Berker1, Chin-Lee Wu1, Piet Habbel2, and Leo L. Cheng1

1Pathology, Massachusetts General Hospital, Charlestown, MA, United States, 2Oncology, Charite Medical University, Berlin, Germany

The gold standard in diagnosing prostate cancer (PCa) is pathological examination of biopsy cores. Still, false negative rates remain between 30-50%. Studies of cancer field effects suggest that tissue without histologically visualizable cancer cells has diagnostic value and could enlarge biopsy target regions. To map metabolic field effects in human prostates, we used HRMAS-MRS to analyze multiple tissue samples throughout entire removed cancer-positive prostates. Evaluation of metabolomic profiles of histologically-benign (Hb) tissue showed that Hb tissues at varying distances to PCa lesions have different metabolic profiles. Hb tissue enables differentiation between clinical parameters (Gleason Score, pathological stage, cancer-affected prostate %).

This abstract and the presentation materials are available to members only; a login is required.

Join Here